Always follow the money. Same old Big Pharma grifters.


At a Senate hearing on Tuesday, Chris Murphy (D-Conn.) questioned Kennedy on MAHA PAC’s industry ties, calling the PAC a “moral and ethical mess.”

Kennedy dismissed the accusations of influence peddling. “I have no idea what companies are making any donations. I have no idea who’s giving money to them,” he said.


But a POLITICO analysis of MAHA PAC and the only other active political action committee aligned with the movement, a linked Super PAC, found they have just over $412,000 in available cash.

What money they have raised has largely come from the pharma industry, whose clout in Washington Kennedy has decried for decades.



“It’s hard to actually refer to MAHA as a movement when you’re looking at just a small number of donors providing the vast majority of financial support,” said Devin Burghart, president of the Institute for Research and Education on Human Rights, a nonprofit watchdog that studies conservative groups.

The MAHA PAC reported only three donations so far in 2026 — two $50,000 contributions from Venni Capital, a little-known New York investment firm whose address links to the headquarters of Chartwell Pharmaceuticals, a generic drug manufacturer and compounding pharmacy that has secured hundreds of millions in contracts with the federal government. Chartwell did not respond to requests for comment.

The third donation came from Botanic Tonics, a kratom and kava beverage company that donated $500,000 in March — the largest donation in the past year and one that follows Kennedy’s crackdown on some kratom-related products last year.

Six of MAHA PAC’s largest donors last year came from entities with interests in biopharma, including OPS International, which sells weight-loss drugs and other wellness products that haven’t received government approval under the name Olympia Pharmaceuticals; biotech firms owned by Lou Reese, a Kennedy ally; and LucyRx, a small pharmacy benefit manager that negotiates drug prices for insurers. Lawmakers have targeted PBMs with recent legislation aimed at lowering drug prices by cutting the middlemen’s fees.